BLIS®

HALF YEAR REPORT

FOR THE SIX MONTHS
TO 30 SEPTEMBER 2026

PROBIOTICS
MADE TO MATTER



CONTENTS

1H27 SUMMARY	1
CHAIR AND CEO REPORT	4
FINANCIAL STATEMENTS	6
COMPANY DIRECTORY	18



1H27 SUMMARY

REVENUE

$8.9m

16% on prior year

B2B REVENUE

$6.3m

19% on prior year

B2C REVENUE

$2.6m

8% on prior year

EBITDA*

$1.2m

$0.7m on prior year

NET PROFIT BEFORE TAX

$1.0m

$0.6m on prior year

* EBITDA is a non-GAAP measure and calculated as Earnings / (loss) before interest, tax, depreciation, amortisation and impairment.

1H27 SUMMARY

REGULATORY AND RESEARCH & DEVELOPMENT PROGRESS



5

New patents granted:

—

Antiviral applications in Europe and Canada

—

Probiotic enhancers in Canada

—

Fermentation in Eurasia and USA



Submissions to NZ Government on dietary supplement regulation



Hired internal regulatory capability to support future endeavours



9

New publications on BLIS K12 and M18 strains



Safe Quality Food (SQF) certification achieved at Dunedin manufacturing plant



Progression of regulatory approval in China and key clinical trial



Progression of development scale up with additional fermentation partner

ENVIRONMENTAL, SOCIAL & GOVERNANCE

- Achieved B Corp™ certification

CONFERENCES BLIS ATTENDED OR PRESENTED AT:

- Hi-Fi China 2026, Shanghai, China
- Probiota Americas 2026, Vancouver, Canada
- Vitafoods Europe 2026, Barcelona, Spain
- Hi Korea 2026, Seoul, South Korea
- Vitafoods Asia 2026, Bangkok, Thailand
- NZTE OEM Matching event, Shanghai, China
- Women's Lifestyle Expo, Wellington, NZ
- Dental Congress 2026, Auckland, NZ
- 2026 NZ Shenzhen Business Forum, Auckland, NZ
- Xiamen University NZ Alumni Association, Auckland, NZ
- NZ Health Supplements Connection, Auckland, NZ
- QMB and Infectious Disease Conference, Christchurch, NZ
- Petfood Industry Webinar
- Nutraceutical World Pet Webinar
- Waikato/BOP Dental Association Conference
- PCNZ Accelerate Programme, Shanghai, China

OTHER

- 2026 Best Places to Work short list
- NZ Marketing Excellence Awards 2026 finalist
- 'Leading at BLIS' programme

BLIS®

Certified B® Corporation

Learn more at bcorp.com













CHAIR AND CEO REPORT





BLIS Technologies Limited (BLIS) delivered revenue of $8.9m for the six month period to 30 September 2026 (1H27), a 16% increase on the same period last year (1H26).

EBITDA was $1.2m, up $0.7m on 1H26, and net profit after tax was $1.0m, up $0.6m on 1H26. The 1H26 result included a one-off supply chain cost increase of $0.8m, which has not recurred in 1H27.

1H27 growth was delivered primarily by B2B, with revenue up 19% on 1H26. B2C revenue was up a more modest 8% on 1H26.

The BLIS balance sheet remains strong. Cash and short term deposits were $9.4m at 30 September 2026, up from $8.8m at 1H26. Operating activities generated a net cash inflow of $1.3m, compared with an outflow of $0.5m in 1H26.

B2B REVENUE

B2B remains the core revenue driver at 71% of total revenue, with revenue of $6.3m for 1H27, up 19% on 1H26.

Ingredient revenue was $4.5m, up 16% on 1H26, with growth led by Asia-Pacific (excluding NZ). Asia-Pacific ingredient revenue was $2.5m, up from $0.3m in 1H26, reflecting strong orders from a key customer in South Korea.

EMEA ingredient revenue was $1.9m, down 39% on 1H26. The prior period was lifted by the carry over of orders into 1Q26 and a shorter reorder time for a major customer.

North America ingredient revenue was $0.1m, down 75% on 1H26, as customers continue to transfer to Probi manufactured ingredient. This shift is reflected in the growth in royalty revenue.

Private label revenue was $0.6m, down 25% on 1H26, reflecting smaller monthly orders as our China business partner sells through product.

Royalty and licensing revenue was $1.2m, up 133% on 1H26, reflecting ongoing commercialisation of licensed BLIS strains through third party brands. This growth is testament to the strength of the partnership with Probi and the joint business plans in place to launch their oral probiotic programme across EMEA and North America.

B2C REVENUE

B2C 1H27 revenue was $2.6m, up 8% on 1H26. Key channel growth occurred in the NZ wholesale channel with pharmacies supported by strong promotional activity and product and training support.

New Zealand wholesale revenue was $1.0m, up 11% on 1H26. The focus has been on winning in key pharmacies and optimised promotions.

Cross-border e-commerce (CBEC) revenue was $0.2m, up 53% on 1H26. The key Chinese partner is achieving strong consumer sell through supported by the joint business plan.

Amazon revenue was $1.0m, down 4% on 1H26. During 1H27, changes to Amazon's certification requirements temporarily affected sales. BLIS fast-tracked Safe Quality Food (SQF) certification, achieving it late in the period and minimising the time affected products were delisted.

The BLIS webstore revenue was $0.4m, up 6% on 1H26. This growth is a solid performance in a challenging domestic economic environment, and reflects focused brand awareness activities and digital strategy optimisation.

OPERATIONAL PROGRESS, REGULATORY AND R&D

Safe Quality Food (SQF) certification was achieved at the Dunedin manufacturing plant during 1H27.

R&D expenditure was $0.8m for 1H27, compared to $0.5m in 1H26. Progress continued on regulatory approval in China and on a key clinical trial, and development scale up advanced with an additional fermentation partner in Europe. BLIS has also established internal regulatory capability and made submissions to the New Zealand Government on dietary supplement regulation.

BLIS continues to invest in patent protection, brand trademarks and new product development. Five new patents were granted in 1H27, covering antiviral applications in Europe and Canada, probiotic enhancers in Canada, and fermentation in Eurasia and the USA. Nine new publications on the BLIS K12 and M18 strains were released during the period. BLIS SynBoost™, a patented synbiotic platform pairing BLIS K12™ and BLIS M18™ with the prebiotic ingredient raffinose to support enhanced probiotic performance, was introduced during the period.

THE BLIS TEAM

BLIS achieved B Corp™ certification in 1H27, following the constitution amendments approved at the August 2025 Annual Shareholder Meeting and progression through the B Lab evaluation process.

This marks a significant milestone in BLIS' commitment to responsible and sustainable business practices. It reaffirms our core purpose of delivering innovation to improve consumers' health and wellbeing, alongside our commitment to high social and environmental performance.

BLIS continued to invest in people and culture, with a successful staff engagement survey completed, and the majority of staff have completed the 'Leading at BLIS' programme. As part of the engagement survey process, BLIS was shortlisted for the 2026 Best Places to Work, which is a testament to the strong culture within the business.

OUTLOOK

BLIS enters 2H27 with a strong base, following 16% revenue growth in 1H27. While we expect the rate of growth to moderate in the second half, we continue to anticipate double-digit revenue growth for the full year.

In 2H27 we will continue to focus on key markets and execution of our joint business plans. We will conclude key regulatory projects and clinical trials currently in progress and commence further research, development and regulatory projects to open new markets and build the clinical evidence base. BLIS remains well positioned for steady, profitable growth in FY27 and beyond, leveraging its science leadership, trusted brand and expanding international partnerships.

As outlined in August at the 2026 Annual Shareholders' Meeting, management is reviewing the medium term capital requirements to accelerate profitable growth through new applications for our probiotic technology and expansion of our international market access.. The Board will review the findings at its December meeting and keep shareholders informed of progress.

As always, we appreciate your support.



Alison Stewart
Chair

Scott Johnson
Chief Executive Officer

FINANCIAL STATEMENTS

FOR THE SIX MONTHS
ENDED 30 SEPTEMBER 2026



CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For the six months ended 30 September 2026

	NOTES	SIX MONTHS 30 SEP 2026 (UNAUDITED) $'000	SIX MONTHS 30 SEP 2025 (UNAUDITED) $'000	12 MONTHS 31 MAR 2026 (AUDITED) $'000
REVENUES				
Revenue	3.1	8,895	7,669	14,668
Other income	3.2	114	142	308
Total revenue and other income		9,009	7,811	14,976
EXPENSES				
Distribution expenses		134	118	294
Marketing expenses		808	851	1,635
Occupancy expenses		81	86	183
Employee benefits		2,180	2,078	4,131
Raw materials and consumables		2,313	2,358	4,134
Operating expenses		2,429	1,853	3,807
Finance expenses		15	23	38
Total expenses	3.3	7,960	7,367	14,222
SURPLUS BEFORE TAX		**1,049**	**444**	**754**
Income tax expense		58	25	62
SURPLUS FOR THE PERIOD		**991**	**419**	**692**
Other comprehensive income		-	-	-
TOTAL COMPREHENSIVE INCOME		**991**	**419**	**692**
Earnings per share:				
Basic (cents per ordinary share)		0.08	0.03	0.05
Diluted (cents per ordinary share)		0.08	0.03	0.05

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the six months ended 30 September 2026

	SHARE CAPITAL (UNAUDITED) $'000	RETAINED EARNINGS/ (DEFICIT) (UNAUDITED) $'000	SHARE BASED PAYMENTS EQUITY RESERVES (UNAUDITED) $'000	TOTAL ATTRIBUTABLE TO GROUP (UNAUDITED) $'000
Opening equity – 1 April 2026	46,689	(33,711)	63	13,041
Surplus for the period	-	991	-	991
Other comprehensive income	-	-	-	-
Total comprehensive income	-	991	-	991
CEO share option equity reserve	40	-	(13)	27
Employee performance rights plan reserve	-	-		-
	40	-	(13)	27
CLOSING EQUITY – 30 SEPTEMBER 2026	**46,729**	**(32,720)**	**50**	**14,059**
Opening equity – 1 April 2025	46,649	(34,403)	76	12,322
Surplus for the period	-	419	-	419
Other comprehensive income	-	-	-	-
Total comprehensive income	-	419	-	419
CEO share option equity reserve	40	-	(12)	28
Employee performance rights plan reserve	-	-		-
	40	-	(12)	28
CLOSING EQUITY – 30 SEPTEMBER 2025	**46,689**	**(33,983)**	**64**	**12,769**

CONSOLIDATED BALANCE SHEET

As at 30 September 2026

	NOTES	30 SEP 2026 (UNAUDITED) $'000	30 SEP 2025 (UNAUDITED) $'000	31 MAR 2026 (AUDITED) $'000
ASSETS				
CURRENT ASSETS				
Cash and cash equivalents		5,913	3,000	4,005
Short term deposits		3,500	5,750	4,500
Trade and other receivables		1,665	1,386	2,051
Prepayments		331	205	477
Inventory		2,232	1,917	1,590
NZX Bond		-	75	-
Foreign exchange contracts		15	-	-
Income tax receivable		16	16	16
Total current assets		13,672	12,349	12,639
NON CURRENT ASSETS				
NZX Bond		75	-	75
Property, plant and equipment		487	531	505
Finite life intangible assets	4	1,477	1,400	1,350
Right-of-use-assets		342	487	399
Total non current assets		2,381	2,418	2,329
TOTAL ASSETS		**16,053**	**14,767**	**14,968**

Continued overleaf / >>

CONSOLIDATED BALANCE SHEET CONTINUED

As at 30 September 2026

	NOTES	30 SEP 2026 (UNAUDITED) $'000	30 SEP 2025 (UNAUDITED) $'000	31 MAR 2026 (AUDITED) $'000
LIABILITIES				
CURRENT LIABILITIES				
Trade and other payables		1,611	1,431	1,479
Lease liabilities		201	178	183
Foreign exchange contracts		-	41	9
Total current liabilities		1,812	1,650	1,671
NON CURRENT LIABILITIES				
Lease liabilities		182	348	256
Total non current liabilities		182	348	256
TOTAL LIABILITIES		**1,994**	**1,998**	**1,927**
NET ASSETS		**14,059**	**12,769**	**13,041**
OWNERS EQUITY				
Share capital	5	46,729	46,689	46,689
Retained earnings / (deficits)		(32,720)	(33,983)	(33,711)
Share based payment equity reserves		50	63	63
TOTAL EQUITY		**14,059**	**12,769**	**13,041**

These financial statements have been authorised for issue on 25 November 2026.



Alison Stewart
Chair



Paul Munro
Director

CONSOLIDATED STATEMENT OF CASHFLOWS

For the six months ended 30 September 2026

	NOTES	SIX MONTHS 30 SEP 2026 (UNAUDITED) $'000	SIX MONTHS 30 SEP 2025 (UNAUDITED) $'000	12 MONTHS 31 MAR 2026 (AUDITED) $'000
CASH FLOWS FROM OPERATING ACTIVITIES				
Cash was provided from / (applied to):				
Receipts from customers		9,350	7,402	13,745
Interest received		45	146	336
Payments to suppliers and employees		(8,073)	(8,016)	(14,642)
Finance costs		(13)	(19)	(34)
Net cash inflow / (outflow) from operating activities	6	1,309	(487)	(595)
CASH FLOWS FROM INVESTING ACTIVITIES				
Cash was provided from / (applied to):				
Proceeds from short term deposits		1,000	-	950
Purchase of short term deposits		-	(300)	-
Purchase of intangible assets		(222)	(233)	(374)
Purchase of property, plant and equipment		(50)	(83)	(125)
Net cash inflow / (outflow) from investing activities		728	(616)	451
CASH FLOWS FROM FINANCING ACTIVITIES				
Cash was provided from / (applied to):				
Repayment of lease liabilities		(94)	(88)	(175)
Receipt of share option		27	27	28
Net cash inflow / (outflow) from financing activities		(67)	(61)	(147)
Net increase / (decrease) in cash held		1,970	(1,164)	(291)
Add cash and cash equivalents at start of period		4,005	4,206	4,206
Foreign exchange differences		(62)	(42)	90
BALANCE AT END OF PERIOD		**5,913**	**3,000**	**4,005**
COMPRISED OF:				
Cash and cash equivalents		5,913	3,000	4,005
		5,913	**3,000**	**4,005**

NOTES TO AND FORMING PART OF THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2026

1. BASIS OF REPORTING

Reporting entity

The unaudited interim consolidated financial statements (Interim Financial Statements) presented are those of BLIS Technologies Limited (the "Company") and its subsidiary BLIS Functional Foods Limited (the "Group").

The Group's principal activity is developing healthcare products and technologies based on proprietary strains of probiotic bacteria for sale and licensing in New Zealand and overseas.

Statutory base

The Company is a profit-oriented entity, domiciled in New Zealand, registered under the Companies Act 1993 and listed on the NZX Main Board (NZX: BLT). The Company is an FMC reporting entity under the Financial Markets Conduct Act 2013. The Interim Financial Statements have been prepared in line with the requirements of these Acts and the Financial Reporting Act 2013.

Basis of Preparation

The Interim Financial Statements have been prepared in accordance with New Zealand Generally Accepted Accounting Practice ("NZ GAAP") and comply with the New Zealand Equivalents to IFRS Accounting Standards ("NZ IFRS"), as appropriate for interim financial statements (NZ IAS 34). The Interim Financial Statements should be read in conjunction with the Group Annual Report for the year ended 31 March 2026.

The Interim Financial Statements were authorised for issue by the Board of Directors on 25 November 2026.

Basis of Measurement

The Interim Financial Statements have been prepared on the historical cost basis, except for the derivative financial instruments that are measured at fair value at the end of each reporting period. Historical cost is based on the fair values of the consideration given in exchange for assets.

Accounting policies are selected and applied in a manner which ensures that the resulting financial information satisfies the concepts of relevance and reliability, thereby ensuring that the substance of the underlying transactions or other events is reported.

The same accounting policies and critical judgements, estimates and assumptions are applied in these Interim Financial Statements as were applied in the preparation of the Group's consolidated financial statements for the year ended 31 March 2026.

The Interim Financial Statements are presented in thousands of New Zealand dollars. The New Zealand dollar is the Group's functional currency.

The Interim Financial Statements do not include all the information required for full financial statements.

Critical Judgements, Estimates and Assumptions

In the application of NZ IFRS, the Directors are required to make judgements, estimates and assumptions about the carrying value of asset and liabilities that are not readily apparent from other sources. The judgements, estimates and assumptions used in the preparation of these Interim Financial Statements are consistent with those used in the Group's consolidated financial statements for the year ended 31 March 2026.

Significant Accounting Policies

The accounting policies in the Interim Financial Statements are the same as those applied in the Group's consolidated financial statements for the year ended 31 March 2026.

The Group has adopted all mandatory new and revised standards and interpretations. None had a material impact on these financial statements.

Certain new standards and interpretations to existing standards have been published but are not yet effective.

The Group expects to adopt these when they become mandatory. Of these, the following standard has been assessed as relevant to the Group:

- NZ IFRS 18 (Presentation and Disclosure in Financial Statements) – introduces new requirements including a change in the structure of the profit and loss, management defined performance measures being included in a note to the financial statements, and enhanced aggregation/disaggregation clarification. The new standard amends the classification in the statement of cash flows.

The Group has assessed that this will impact on the presentation of the Consolidated Statement of Comprehensive income and the Consolidated Statement of Cashflows for the current and comparative period. The notes forming part of the Consolidated Financial Statements will be updated to include a reconciliation for any management defined performance measures to the most directly comparable IFRS subtotals.

2. SIGNIFICANT TRANSACTIONS AND EVENTS FOR THE CURRENT PERIOD

There were no significant transactions and events that affected the financial performance and financial position of the Group for the six-month period ended 30 September 2026.

3. REVENUE AND OTHER INCOME

3.1 Revenue

	SIX MONTHS 30 SEP 2026 (UNAUDITED) $'000	SIX MONTHS 30 SEP 2025 (UNAUDITED) $'000	12 MONTHS 31 MAR 2026 (AUDITED) $'000
Revenue consists of the following items:			
Point in time recognition:			
Sale of goods – domestic sales			
Finished goods	1,388	1,224	2,224
Ingredients	45	-	-
License fee and royalties	5	7	17
Sale of goods – export sales			
Finished goods	1,816	2,037	3,891
Ingredients	4,471	3,903	7,289
License fee and royalties	1,170	498	1,247
	8,895	**7,669**	**14,668**

3.2 Other Income

	SIX MONTHS 30 SEP 2026 (UNAUDITED) $'000	SIX MONTHS 30 SEP 2025 (UNAUDITED) $'000	12 MONTHS 31 MAR 2026 (AUDITED) $'000
Grant income	-	7	41
Interest income	114	135	263
Other income	-	-	4
	114	**142**	**308**

3.3 Expenses

	SIX MONTHS 30 SEP 2026 (UNAUDITED) $'000	SIX MONTHS 30 SEP 2025 (UNAUDITED) $'000	12 MONTHS 31 MAR 2026 (AUDITED) $'000
This includes the following expenses:			
Research and development expense	801	476	933
Includes:			
Employee benefits	384	294	622

4. FINITE LIFE INTANGIBLE ASSETS

	TRADEMARKS $'000	PATENTS $'000	CAPITALISED DEVELOPMENT $'000	IT, WEBSITE DEVELOPMENT AND SOFTWARE $'000	TOTAL $'000
30 SEPTEMBER 2026 (UNAUDITED)					
Gross Carrying Amount					
Balance at 1 April 2026	636	1,824	4,103	400	6,963
Additions	23	106	93	-	222
Disposals	-	(1,043)	(292)	(153)	(1,488)
Balance at 30 September 2026	659	887	3,904	247	5,697
Accumulated amortisation and impairment					
Balance at 1 April 2026	217	1,135	3,861	400	5,613
Amortisation expense	30	20	45	-	95
Disposals	-	(1,043)	(292)	(153)	(1,488)
Balance at 30 September 2026	247	112	3,614	247	4,220
Net book value at 30 September 2026	**412**	**775**	**290**	**-**	**1,477**
30 SEPTEMBER 2025 (UNAUDITED)					
Gross Carrying Amount					
Balance at 1 April 2025	559	1,627	4,103	400	6,689
Additions	77	156	-	-	233
Disposals	-	-	-	-	-
Balance at 30 September 2025	636	1,783	4,103	400	6,922
Accumulated amortisation and impairment					
Balance at 1 April 2025	163	1,093	3,771	399	5,426
Amortisation expense	28	23	45	1	97
Balance at 30 September 2025	191	1,116	3,816	400	5,523
Net book value at 30 September 2025	**445**	**667**	**287**	**-**	**1,399**
31 MARCH 2026 (AUDITED)					
Gross Carrying Amount					
Balance at 1 April 2025	559	1,627	4,103	400	6,689
Additions	118	256	-	-	374
Disposals	(41)	(59)	-	-	(100)
Balance at 31 March 2026	636	1,824	4,103	400	6,963
Accumulated amortisation and impairment					
Balance at 1 April 2025	163	1,093	3,771	399	5,426
Amortisation expense	58	48	90	1	197
Disposals	(4)	(6)	-	-	(10)
Balance at 31 March 2026	217	1,135	3,861	400	5,613
Net book value at 31 March 2026	**419**	**689**	**242**	**-**	**1,350**

5. SHARE CAPITAL

	30 SEP 2026 (UNAUDITED)		30 SEP 2025 (UNAUDITED)		31 MAR 2026 (AUDITED)	
	NO. OF SHARES	$'000	NO. OF SHARES	$'000	NO. OF SHARES	$'000
Balance at the beginning of the period (fully paid)	1,279,301,599	46,689	1,279,301,599	46,649	1,279,301,599	46,649
Shares pursuant to CEO share plan	-	40	-	40	-	40
Balance at the end of the period	**1,279,301,599**	**46,729**	**1,279,301,599**	**46,689**	**1,279,301,599**	**46,689**

6. RECONCILIATION OF NET SURPLUS WITH CASHFLOWS FROM OPERATING ACTIVITIES

	SIX MONTHS 30 SEP 2026 (UNAUDITED) $'000	SIX MONTHS 30 SEP 2025 (UNAUDITED) $'000	12 MONTHS 31 MAR 2026 (AUDITED) $'000
NET SURPLUS FOR THE PERIOD	**991**	**419**	**692**
Adjustments for non-cash items:			
Amortisation	95	96	197
Depreciation property, plant and equipment	68	65	133
Depreciation right of use assets	97	45	133
Foreign exchange loss / (gain)	61	42	(88)
Lease liability adjustment	(2)	-	4
Loss / (gain) on fair value of foreign exchange contracts	(24)	34	2
Loss on disposal of intangible assets	-	-	90
	1,286	705	1,163
Movement in working capital			
Trade and other receivables	386	(321)	(984)
Prepayments	146	202	(72)
Inventories	(642)	(1,189)	(862)
Income tax receivable	-	62	62
Trade and other payables	133	54	98
	23	(1,192)	(1,758)
NET CASH INFLOW / (OUTFLOW) FROM OPERATING ACTIVITIES	**1,309**	**(487)**	**(595)**

7. CAPITAL COMMITMENTS, CONTINGENT ASSETS AND CONTINGENT LIABILITIES

There are $43k capital commitments as at 30 September 2026 (30 September 2025: Nil). There are no material contingent assets or contingent liabilities as at 30 September 2026 (30 September 2025: Nil).

8. INVESTMENT IN SUBSIDIARY

	PERCENTAGE HELD				
SUBSIDIARY	30 SEP 2026	30 SEP 2025	31 MAR 2026	BALANCE DATE	PRINCIPAL ACTIVITY
BLIS Functional Foods Limited	100%	100%	100%	31 March	Non-trading

9. SEGMENTAL REPORTING

9.1 Operating Segments

The Group is internally reported as a single operating segment to the chief operating decision-maker.

9.2 Revenue from major products and services

	SIX MONTHS 30 SEP 2026 (UNAUDITED) $'000	SIX MONTHS 30 SEP 2025 (UNAUDITED) $'000	12 MONTHS 31 MAR 2026 (AUDITED) $'000
The Group's revenues from its major products and services were as follows:			
BLIS products	8,895	7,669	14,668
Non-core business	114	142	308
Total revenue and other income	**9,009**	**7,811**	**14,976**

Non-core revenues include interest received, grant and other revenue.

9.3 Information about geographical areas

	REVENUE FROM EXTERNAL CUSTOMERS			NON CURRENT ASSETS		
	SIX MONTHS 30 SEP 26 (UNAUDITED) $'000	SIX MONTHS 30 SEP 25 (UNAUDITED) $'000	12 MONTHS 31 MAR 26 (AUDITED) $'000	SIX MONTHS 30 SEP 26 (UNAUDITED) $'000	SIX MONTHS 30 SEP 25 (UNAUDITED) $'000	12 MONTHS 31 MAR 26 (AUDITED) $'000
New Zealand	1,438	1,231	2,241	2,381	2,418	2,329
Asia Pacific (excl. NZ)	3,322	1,302	3,573	-	-	-
EMEA	1,869	3,171	4,353	-	-	-
North America	2,266	1,965	4,501	-	-	-
Total revenue	**8,895**	**7,669**	**14,668**	**2,381**	**2,418**	**2,329**
Grant revenue	-	7	41	-	-	-
Interest revenue	114	135	263	-	-	-
Other revenue	-	-	4	-	-	-
Total revenue and other income	**9,009**	**7,811**	**14,976**	**2,381**	**2,418**	**2,329**

Revenues for the six months to 30 September 2026 include $1,836k, $1,731k, and $1,257k, which arose from sales, license fees and royalties to the Group's three largest customers.

Revenues for the six months to 30 September 2025 include $3,146k, $943k, and $786k, which arose from sales, license fees and royalties to the Group's three largest customers.

Revenues for the year ended 31 March 2026 include $4,302k, $2,339k and $1,350k which arose from sales, license fees and royalties to the Group's three largest customers.

10. SUBSEQUENT EVENTS

There were no subsequent events post 30 September 2026 (2025: Nil).

COMPANY DIRECTORY

COMPANY NUMBER

1042367

ISSUED CAPITAL

1,279,301,599 Ordinary Shares

REGISTERED OFFICE

BLIS Technologies Limited
399 Moray Place,
Dunedin Central, Dunedin 9016

SHAREHOLDERS

NZX LISTING – Listed on the NZX Main Board

SHARE REGISTRAR

MUFG Corporate Markets
Level 30, PwC Tower
15 Customs Street West
Auckland 1010

DIRECTORS

Dr A Stewart
A Johansen
A McCammon
Dr B Richardson
P Munro

CHIEF EXECUTIVE

S Johnson

AUDITORS

Deloitte Limited

BANKERS

Bank of New Zealand

SOLICITORS

Anderson Lloyd
A J Park

WEBSITE

www.blis.co.nz
www.blisprobiotics.co.nz

FACEBOOK

www.facebook.com/BLISProbioticsNZ

INSTAGRAM

www.instagram.com/blisprobiotics

LINKEDIN

www.linkedin.com/company/blis-technologies-limited


BLIS PROBIOTICS®
FRESH BREATH™
KIT
Probiotics to support & maintain fresh healthy breath
4 WEEK KIT CONTAINS:
+ 40 BLIS K12™ LOZENGES
+ MOUTHWASH
+ TONGUE CLEANER
+ MEASURING CUP
CONTAINS BLIS K12
DIETARY SUPPLEMENT
BLIS PROBIOTICS®
TOOTH GUARD®
Probiotic support for healthy teeth & gums
+ TAKE DAILY
+ 30 LOZENGES
BLIS M18
DIETARY SUPPLEMENT
Peppermint Lozenges
BLIS PROBIOTICS®
TOOTH GUARD™
JUNIOR
Probiotic support for healthy teeth & gums
+ TAKE DAILY
+ 30 LOZENGES
BLIS M18
DIETARY SUPPLEMENT
Strawberry Lozenges



BLIS Technologies Limited
Physical address: 399 Moray Place, Dunedin 9016
Postal address: PO Box 2208, Dunedin 9044, New Zealand
info@blis.co.nz | +64 3 474 0988 | **www.blis.co.nz**